Funds Holding Depomed, Inc.

 
Fund Quotes for Funds Holding Depomed, Inc. top ^
  • Holdings: CU Cv 1.875% , Rambus Inc Del Cv 1.125% , Scorpio Tankers 144A Cv 2.375% , Acorda Therapeutics Cv 1.75% , Depomed Cv 2.5% ,
  • Category: Convertibles
  • Morningstar Rating: 2 Stars
Sign-up for dnaix investment picks
  • Holdings: CU Cv 1.875% , Rambus Inc Del Cv 1.125% , Scorpio Tankers 144A Cv 2.375% , Acorda Therapeutics Cv 1.75% , Depomed Cv 2.5% ,
  • Category: Convertibles
  • Morningstar Rating: 1 Stars
Sign-up for dcaix investment picks
  • Holdings: CU Cv 1.875% , Rambus Inc Del Cv 1.125% , Scorpio Tankers 144A Cv 2.375% , Acorda Therapeutics Cv 1.75% , Depomed Cv 2.5% ,
  • Category: Convertibles
  • Morningstar Rating: 1 Stars
Sign-up for daaix investment picks
  • Holdings: CU Cv 1.875% , Rambus Inc Del Cv 1.125% , Scorpio Tankers 144A Cv 2.375% , Acorda Therapeutics Cv 1.75% , Depomed Cv 2.5% ,
  • Category: Convertibles
  • Morningstar Rating: 2 Stars
Sign-up for daaix investment picks

 
Stock Quotes for Depomed, Inc. top ^
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Slow Growth
Sign-up for depo investment picks

 
News Articles for Depomed, Inc. top ^
2014/11/5
- Record quarterly product revenues, up 88% over third quarter 2013 - Gralise court victories extend expected exclusivity to 2024 - Over half billion dollars in cash and marketable securities for future acquisitions - Conference call scheduled for today at 4:30 p.m. EST NEWARK, Calif.
Sign-up for Depomed Reports Third Quarter 2014 Financial Results investment picks
NEWARK, Calif.
Sign-up for Depomed To Present At Stifel 2014 Healthcare Conference investment picks
NEWARK, Calif.
Sign-up for Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference investment picks
By Josh Beckerman Deal to position Depomed as pain, neurology focused company Johnson & Johnson unit Janssen Pharmaceuticals Inc. has agreed to sell its U.S. license rights to the painkiller Nucynta to Depomed Inc. for $1.05 billion.
Sign-up for DepoMed to buy U.S. rights to Nucynta from J&J unit investment picks
Conference call today at 5:00 p.m. EST - Transformative acquisition enhances Depomed's position as a leading pain and neurology focused specialty pharmaceutical company - Adds significant revenue and immediate earnings impact upon expected second quarter closing; increases Depomed 2014 pro forma net product revenues by approximately 2.5 times compared to recent company guidance - Expected to be immediately accretive to non-GAAP EPS in 2015, with significant growth in net sales, EBITDA, non-GAAP earnings and cash flow beyond that timeframe - Strong fundamental returns - return on invested capital estimated to exceed cost of capital by 2016 - Directly leverages Depomed's existing infrastructure and expertise with pain specialists, neurologists and primary care physicians - Intellectual property provides lengthy period of market exclusivity NEWARK, Calif.
Sign-up for Depomed to Acquire U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) Oral Solution from Janssen Pharmaceuticals, Inc. for $1.05 billion investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Funds Holding Depomed, Inc.
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Funds Holding Dentsply International, Inc.  |  Next: Funds Holding Derma Sciences, Inc.